Literature DB >> 12392802

Heroin detoxification with buprenorphine on an inpatient psychiatric unit.

Bethany A DiPaula1, Robert Schwartz, Ivan D Montoya, David Barrett, Cecilia Tang.   

Abstract

The purpose of this open-label, uncontrolled study was to evaluate the feasibility of administering off-label buprenorphine in combination with ancillary medications for inpatient short-term detoxification of heroin-dependent patients at a psychiatric facility. A sample of 20 heroin-dependent patients admitted to an urban psychiatric hospital was administered buprenorphine 6, 4, and 2 mg/day during the first, second, and third day of detoxification, respectively, and then observed during the fourth and fifth day. Eighty-five percent of the subjects abused other substances, 75% reported cocaine abuse/dependence, 75% had comorbid mood disorders. All subjects completed the medication phase of the study. No clinically significant adverse events were reported. There was a significant decrease in the Clinical Investigation Narcotic Assessment (CINA) total score between baseline and days 2 through 5. The results suggest that buprenorphine is well tolerated and may be beneficial for medically supervised short-term withdrawal from heroin for hospitalized psychiatric patients. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12392802      PMCID: PMC2633653          DOI: 10.1016/s0740-5472(02)00244-1

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  21 in total

1.  Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.

Authors:  L Amass; J B Kamien; S K Mikulich
Journal:  Drug Alcohol Depend       Date:  2000-02-01       Impact factor: 4.492

2.  Three methods of opioid detoxification in a primary care setting. A randomized trial.

Authors:  P G O'Connor; K M Carroll; J M Shi; R S Schottenfeld; T R Kosten; B J Rounsaville
Journal:  Ann Intern Med       Date:  1997-10-01       Impact factor: 25.391

Review 3.  Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research.

Authors:  K B Wells
Journal:  Am J Psychiatry       Date:  1999-01       Impact factor: 18.112

4.  Remission of substance use disorder among psychiatric inpatients with mental illness.

Authors:  L Dixon; S McNary; A F Lehman
Journal:  Am J Psychiatry       Date:  1998-02       Impact factor: 18.112

Review 5.  Co-occurring severe mental illness and substance use disorders: a review of recent research.

Authors:  J RachBeisel; J Scott; L Dixon
Journal:  Psychiatr Serv       Date:  1999-11       Impact factor: 3.084

Review 6.  Buprenorphine for the management of opioid withdrawal.

Authors:  L Gowing; R Ali; J White
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 7.  Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.

Authors:  L Dixon
Journal:  Schizophr Res       Date:  1999-03-01       Impact factor: 4.939

Review 8.  Opioid antagonists and adrenergic agonists for the management of opioid withdrawal.

Authors:  L Gowing; R Ali; J White
Journal:  Cochrane Database Syst Rev       Date:  2000

9.  [Buprenorphine as a new alternative for detoxification of heroin addicts. It causes only mild withdrawal problems, abating quickly].

Authors:  G Blennow; A Fergusson; A Medvedeo
Journal:  Lakartidningen       Date:  2000-04-12

10.  Naltrexone shortened opioid detoxification with buprenorphine.

Authors:  A Umbricht; I D Montoya; D R Hoover; K L Demuth; C T Chiang; K L Preston
Journal:  Drug Alcohol Depend       Date:  1999-10-01       Impact factor: 4.492

View more
  5 in total

1.  Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomes.

Authors:  Maureen Hillhouse; Catherine P Domier; David Chim; Walter Ling
Journal:  J Addict Dis       Date:  2010-01

2.  Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial.

Authors:  Sudie E Back; Rebecca L Payne; Amy Herrin Wahlquist; Rickey E Carter; Zachary Stroud; Louise Haynes; Maureen Hillhouse; Kathleen T Brady; Walter Ling
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

Review 3.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

4.  Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention.

Authors:  Amber M Holbrook; Hendree E Jones; Sarah H Heil; Peter R Martin; Susan M Stine; Gabriele Fischer; Mara G Coyle; Karol Kaltenbach
Journal:  Drug Alcohol Depend       Date:  2013-03-21       Impact factor: 4.492

5.  Default Mode Network Functional Reorganization During Early Abstinence in Polysubstance-Using Emerging Adults Treated for Opioid Dependence.

Authors:  Marc L Copersino; Jenessa S Price; Katherine H Frost; Gordana D Vitaliano; Blaise deB Frederick; Scott E Lukas; Roger D Weiss; Amy C Janes
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2016-01-21       Impact factor: 2.198

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.